U.S. markets closed
  • S&P Futures

    3,827.25
    +1.75 (+0.05%)
     
  • Dow Futures

    30,950.00
    +17.00 (+0.05%)
     
  • Nasdaq Futures

    11,681.50
    +7.25 (+0.06%)
     
  • Russell 2000 Futures

    1,739.00
    +0.70 (+0.04%)
     
  • Crude Oil

    111.03
    -0.73 (-0.65%)
     
  • Gold

    1,823.10
    +1.90 (+0.10%)
     
  • Silver

    20.78
    -0.03 (-0.12%)
     
  • EUR/USD

    1.0532
    +0.0007 (+0.06%)
     
  • 10-Yr Bond

    3.2060
    +0.0120 (+0.38%)
     
  • Vix

    28.36
    +1.41 (+5.23%)
     
  • GBP/USD

    1.2205
    +0.0020 (+0.17%)
     
  • USD/JPY

    136.0350
    -0.0930 (-0.07%)
     
  • BTC-USD

    20,331.93
    -267.72 (-1.30%)
     
  • CMC Crypto 200

    440.83
    -9.23 (-2.05%)
     
  • FTSE 100

    7,323.41
    +65.09 (+0.90%)
     
  • Nikkei 225

    26,756.04
    -293.43 (-1.08%)
     

Arvinas Highlights New ARV-110 Data In Prostate Cancer Patients

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

Arvinas Inc (NASDAQ: ARVN) announced the presentation of new data from completed Phase 1 dose-escalation and ongoing Phase 2 ARDENT expansion cohort with bavdegalutamide (ARV-110).

  • The data were shared at the 2022 American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium.

  • The data showed that bavdegalutamide continues to provide evidence of anti-tumor activity and patient benefit in metastatic castration-resistant prostate cancer (mCRPC).

  • Bavdegalutamide reduced prostate-specific antigen (PSA) levels greater than or equal to 50% (PSA50) in 46% of patients with tumors harboring AR T878X/H875Y mutations.

  • Also See: Arvinas, Pfizer's ARV-471 Shows Clinical Benefit Rate Of 40% In Pretreated Breast Cancer Patients.

  • The Company plans to initiate a pivotal trial by year-end 2022.

  • Two confirmed partial responses were observed out of seven evaluable patients with AR T878X/H875Y tumor mutations.

  • PSA50 rate of 26% (five of 19) in evaluable patients in the subgroup defined as "less pretreated" (having received only one prior hormonal agent and no prior chemotherapy).

  • Most treatment-related adverse events (TRAEs) were mild to moderate, and there were no serious/life-threatening TRAEs in the 113 patients treated at the recommended 420 mg dose.

  • Price Action: ARVN shares were down 4.93% at $71.82 during the market session on the last check Tuesday.

See more from Benzinga

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.